Dietary Patterns and Symptomatic Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Chang Xu, Nathalie Marchand, Jeffrey Driban et. al.

Nov 13th, 2019 - Background/Purpose: Osteoarthritis (OA) is a major source of disability worldwide yet dietary exposures that might be associated with its progression have not received significant research attention. We aimed to examine the prospective association of major dietary patterns derived by principal component analysis (PCA) with symptomatic progression of knee OA. Methods: From the Osteoarthritis Ini...

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Contro...
Philip Mease, Laure Gossec, Laura Coates et. al.

Nov 13th, 2019 - Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of significant inflammatory disease activity’.1,2 Since many patients with PsA may not achieve clinical remission, treatment recommendations recognise minimal or low disease activity as an important alternative treatment t...

Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?
Hiral Master, Tuhina Neogi, Lavalley Michael et. al.

Nov 13th, 2019 - Background/Purpose: Slow walking speed (WS) is a risk factor for mortality in well-functioning older adults and speeds slower than (< ) 1.22 meters per second (m/s) are a risk factor for poor health outcomes in knee osteoarthritis (OA). WS is known to decline with age, with some declining faster than other, though it is unclear if the rate of decline in WS is additionally relevant for mortality...

Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
Francine Castillo, Adrienne Strait, Michael Evans et. al.

Nov 13th, 2019 - Background/Purpose: Prednisone is commonly used to treat rheumatic diseases, yet few comparative effectiveness studies on different dosing regimens are available. Electronic health records (EHR) and prescriptions are potential data sources for such research. However, a barrier to this work is organizing non-standardized prednisone “sigs”, or free-text instructions within a prescription, into a ...

DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Elise van Mulligen, Angelique Weel, Martijn Kuijper et. al.

Nov 13th, 2019 - Background/Purpose: In rheumatoid arthritis (RA) disease outcomes  have improved enormously in the last  decades. Due to early initiation of therapy, a treat-to-target approach and a growing arsenal of disease-modifying antirheumatic drugs (DMARDs) and biologicals, RA patients are in sustained remission more often. This raises the subsequent questions whether treatment should be continued, tape...

Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
Ginto Pottackal, James Travis, Rosemarie Neuner et. al.

Nov 13th, 2019 - Background/Purpose: In April 2019, FDA approved the first treatment, intravenous (IV) belimumab (BEL), specifically for children 5 to 17 years of age with active, seropositive SLE receiving standard care (SOC). The approval was supported by a single post-marketing required randomized, controlled trial (NCT01649765) that evaluated the efficacy, safety and pharmacokinetics (PK) of 10 mg/kg IV BEL...

Access to Care and Diagnostic Delays in Juvenile Dermatomyositis
Jessica Neely, Susan Kim, Hugh Sturrock 2 and Julia Shalen et. al.

Nov 13th, 2019 - Background/Purpose: Factors associated with diagnostic delay in Juvenile Dermatomyositis (JDM) are not known.  We hypothesized that limited access to pediatric rheumatologists can lead to delay in the diagnosis of JDM and worse outcomes. We investigated demographic factors, including access to care, associated with diagnostic delays and clinical outcomes of subjects with JDM in the Childhood Ar...

An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases
Chiara Bellocchi, Álvaro Fernández-Ochoa, Gaia Montanelli et. al.

Nov 13th, 2019 - Background/Purpose: Gut microbiota may be relevant in the regulation of immune processes and in the development of systemic autoimmune diseases (SADs). A reduction of microbiota diversity and a selective decrease of commensal pro-regolatory bacteria have been observed in systemic lupus erythematosus (SLE), Sjogren syndrome (SJS) and primary anti-phosholipid syndrome (PAPS). None studies have be...

Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Aron H Bjornsson, Olafur Palsson, Mar Kristjansson et. al.

Nov 13th, 2019 - Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are needed. Our objective was to investigate the use of antimicrobials (antibiotics, antifungals and antivirals; excluding antimycobacterials) in patients with rheumatoid arthritis (R...

The Effects of Leisure Time Sitting and Sitting at Work on Worsening Radiographic Knee Osteoarthritis over Two Years: Data from the Osteoarthritis Initiative
Dana Voinier, Tuhina Neogi, Hiral Master et. al.

Nov 13th, 2019 - Background/Purpose: Sitting is associated with many poor health outcomes, which may include knee osteoarthritis (OA). When the knee is subject to minimal load, knee cartilage becomes thinner and may be more susceptible to damage. Thus, people who spend more time in sitting, whether during leisure time or during work, may be at greater risk for worsening structural damage in the knee. We examine...

The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Chary Lopez-Pedrera, Alejandro Ibañez-Costa, Mª Ángeles Aguirre-Zamorano et. al.

Nov 13th, 2019 - Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing machinery of immune cells could influence the development and activity of the disease and the kidney involvement in systemic lupus erythematosus (SLE) patients. Methods: Monocytes, lymphocytes and neutrophils from 43 SLE patients and 34 healthy donors (HD) were purified by immunomagnetic selection. The...

Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Ali Yazdanyar, Anthony Donato, Kathleen McElwee et. al.

Nov 13th, 2019 - Background/Purpose: To assess the risk of 30-day readmission, mortality, and adverse events among adults with Rheumatoid Arthritis as compared to Osteoarthritis after primary hip or knee arthroplasty. Methods: We identified index hospitalizations with a principal procedure of primary HA or KA using a nationally representative U.S. sample, the Nationwide Readmission Database (2010-2013).  Exclud...

Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Vera Golder, Molla Huq, Rangi Kandane-Rathnayake et. al.

Nov 13th, 2019 - Background/Purpose: The Lupus Low Disease Activity State (LLDAS) is a treatment endpoint for SLE that has been shown in prospective validation studies to be associated with protection against disease flares and damage accrual. In addition to improved physician-measured outcomes, attainment of treatment endpoints should also result in improvement in patient-reported outcomes such as health relat...

Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Allan Klein, David Lin, Paul Cremer et. al.

Nov 13th, 2019 - Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects 20-30 % of acute pericarditis patients. IL-1α/β, mediators of the inflammatory process, predominate in recurrent pericarditis (RP). Methods: Participants with symptomatic or corticosteroid (CS)-dependent idiopathic or post...

Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD
Julia Sun, Charles Oshinsky, Nicole Garcia et. al.

Nov 13th, 2019 - Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality and carries significant morbidity in connective tissue disease (CTD). Corticosteroids are often used as first line therapy, yet the use of additional immunosuppressive (IS) agents remains largely empiric. In this study we evaluated the effect of Rituximab (RTX) as rescue therapy on lung function in a cohort of...

Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Hanna Källmark, Jon Einarsson, Jan-Åke Nilsson 3 and Meliha Kapetanovic et. al.

Nov 13th, 2019 - Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX), and treatment escalation in case of insufficient response. In this scenario, similar efficacy of biological DMARDs (bDMARDs)  + MTX compared to conventional triple ...

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in P...
Philip Mease, Saima Chohan, Ferran J. García Fructuoso et. al.

Nov 13th, 2019 - Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the 24-week efficacy and safety results from a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b TIL study in patients with active PsA (NCT02980692). Methods...

From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Natalie McCormick, Zachary Wallace, Chio Yokose et. al.

Nov 13th, 2019 - Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout medications, including colchicine.  Used for decades, its price rose drastically after one brand-name form (Colcrys) was granted market exclusivity from 2011-2014, as part of the FDA Unapproved Drugs Initiative. We quantified changes in total spending...

Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
Amit Saxena, Peter Izmirly, Rebecca Bomar et. al.

Nov 13th, 2019 - Background/Purpose: Cardiac manifestations of neonatal lupus (NL) have been associated with significant morbidity and mortality, however there has been minimal information on long-term outcomes of affected individuals.  This study was initiated to evaluate the presence of and risk factors associated with cardiac dysfunction in NL after birth in multiple age groups to improve counseling, further...

Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis
Hemant Suryawanshi, Robert Clancy, Evan Der et. al.

Nov 13th, 2019 - Background/Purpose: The impact of renal injury in lupus nephritis (LN) is widespread with consequences to resident cells in other tissue beds, even non-lesional, non-sun exposed skin. Faithful reflection of a relevant renal tissue pathway in a more readily accessible compartment would allow for less invasive diagnostic alternatives. While ongoing studies are exploiting single cell RNA sequencin...